
Altimmune, Inc.: updates and filings
Price
$1.33
November 20, 2026Market cap $259M
What Ploutos Investor adds for Altimmune
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
September 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operationsForm8-K
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 29, 2026New material financial obligationForm8-K
- Oct 27, 2026Officer or director change, Regulation FD disclosureForm8-K
- Sep 29, 2026Officer or director changeForm8-K
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operationsForm8-K
- Jul 28, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 16, 2026Other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 13, 2026Shares registered for employeesFormS-8
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 24, 2026Material agreement enteredForm8-K
- Apr 22, 2026FilingFormS-3MEF
- Apr 16, 2026Amended articles or bylaws, shareholder voteForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 17, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 29, 2026 | 8-K | New material financial obligation | Document |
| Oct 27, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Sep 29, 2026 | 8-K | Officer or director change | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Jul 28, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 16, 2026 | 8-K | Other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 13, 2026 | S-8 | Shares registered for employees | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 24, 2026 | 8-K | Material agreement entered | Document |
| Apr 22, 2026 | S-3MEF | Filing | Document |
| Apr 16, 2026 | 8-K | Amended articles or bylaws, shareholder vote | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 17, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 6, 2005.
The full analysis
What do Altimmune's filings show?
The filings are where every one of Altimmune's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.